![](/wp-content/uploads/2018/10/rEGM2FQ0TL6PA0pInK6t.png)
$599
Zegalogue (Dasiglucagon) Label Analysis
Zealand recently announced its dasiglucagon hypoglycemia rescue product, branded as “Zegalogue,” received FDA approval (view label; previous FENIX insight). Following the approval, Zealand hosted an investor webcast to provide additional details surrounding the commercialization of Zegalogue (view slides). Below, FENIX has conducted a Zegalogue label analysis in the context of Lilly’s Baqsimi and Xeris’s Gvoke.